Connecticut 2023 2023 Regular Session

Connecticut Senate Bill SB01102 Comm Sub / Analysis

Filed 03/27/2023

                     
Researcher: JSB 	Page 1 	3/27/23 
 
 
 
 
OLR Bill Analysis 
sSB 1102  
 
AN ACT CONCERNING PHARMACIES AND PHARMACISTS.  
 
SUMMARY 
This bill makes changes in the laws concerning pharmacists and 
consumer access to medications. Specifically, it: 
1. establishes a licensing process for institutional pharmacies 
located in health care facilities (e.g., hospitals) to compound 
sterile pharmaceuticals and sell them at retail; 
2. allows pharmacists to order and administer tests for COVID-19, 
HIV, and influenza;  
3. allows pharmacists to prescribe and dispense HIV-related 
prophylaxis if a patient tests negative after a pharmacist-
administered HIV test; 
4. expands the vaccine types that pharmacists can administer; 
5. allows pharmacists to administer an epinephrine cartridge 
injector to someone experiencing anaphylaxis; 
6. allows pharmacies to operate mobile pharmacies in temporary 
locations with the Department of Consumer Protection’s (DCP) 
approval;  
7. requires pharmacies to maintain a plan to manage unscheduled 
closings and specifies actions that can and must be taken during 
these closures; and  
8. requires DCP to adopt regulations on prescription pickup lockers 
at pharmacies, but allows for their use before the regulations are 
adopted under specified circumstances.  2023SB-01102-R000221-BA.DOCX 
 
Researcher: JSB 	Page 2 	3/27/23 
 
The bill also makes minor, technical, and conforming changes.   
EFFECTIVE DATE: July 1, 2023 
§§ 1 & 6-16 — HEALTH CARE INSTITUTIONAL PHARMACIES’ 
STERILE COMPOUNDING 
The bill establishes a process to allow institutional pharmacies 
located in licensed healthcare facilities (“health care institutional 
pharmacies”) to compound sterile pharmaceuticals for retail sale and 
subjects them to the same requirements that apply to other retail 
pharmacies compounding sterile pharmaceuticals. Under current law, 
health care institutional pharmacies (1) are generally not licensed as 
pharmacies and (2) do not compound sterile pharmaceuticals for retail 
sale. The bill authorizes DCP to adopt regulations creating a class or 
classes of pharmacy licenses specifically for health care institutional 
pharmacies. It also explicitly authorizes health care institutions to apply 
for a pharmacy license, subject to the same existing licensure 
requirements as pharmacists and others applying for a license.   
Sterile Compounding for Retail Sales 
Under existing law, if a pharmacy licensee intends to compound 
sterile pharmaceuticals, it must seek DCP’s approval by applying for an 
addendum to its pharmacy license application and submitting to a DCP 
inspection. The bill requires a health care institutional pharmacy that 
wants to sell compounded sterile pharmaceuticals at retail to obtain a 
pharmacy license and similarly apply for an addendum and undergo an 
inspection.    
By deeming health care institutional pharmacies that compound 
sterile pharmaceuticals for retail sale “sterile compounding 
pharmacies,” the bill also subjects them to the same requirements that 
apply to other retail pharmacies (e.g., required notices to DCP), 
including requirements adopted by regulation.   
Compounding for Non-Retail Uses 
Under current law, if an institutional pharmacy within a licensed 
health care facility compounds sterile pharmaceuticals, it does not need  2023SB-01102-R000221-BA.DOCX 
 
Researcher: JSB 	Page 3 	3/27/23 
 
to apply for DCP approval, but like other sterile compounding 
pharmacies, it must comply with applicable state, federal, and U.S. 
Pharmacopeia standards, unless it receives a temporary extension to do 
so. The bill generally eliminates provisions in law regulating these 
institutional pharmacies’ compounding of sterile pharmaceuticals and 
specifies that the law on retail sterile compounding pharmacies does not 
prohibit a licensed hospital from compounding sterile pharmaceuticals 
for its patients consistent with federal law. In doing so, it also eliminates 
provisions specifically requiring institutional pharmacies to (1) prepare 
and maintain a policy and procedure manual and (2) inform DCP which 
pharmacist is responsible for overseeing the compounding of sterile 
pharmaceuticals. 
§§ 2 & 5 — EXPANDING PHARMACISTS’ SCOPE OF PRACTICE  
The bill expands pharmacists’ scope of practice by authorizing them 
to (1) administer additional vaccinations and epinephrine cartridge 
injectors (§ 5); (2) order and administer COVID-19, HIV, and influenza 
related tests (§ 2); and (3) prescribe HIV-related prophylaxis if an HIV 
test they ordered and administered comes back negative (§ 2).   
Vaccinations  
By law, pharmacists who comply with DCP regulations on vaccine 
administration training may administer to adults any approved vaccine 
on the Centers for Disease Control and Prevention’s (CDC) adult 
immunization schedule. Currently, for children ages 12-17, they may 
administer an influenza vaccine ordered by a health care provider if 
they have the parent or guardian’s consent. (Additionally, under 
temporary federal rules (see BACKGROUND) , pharmacists can 
currently administer various vaccines to children ages 3 and older.) 
The bill permanently expands the types of vaccines pharmacists can 
administer to people ages 12 or older. Under the bill, they must be 
administered in compliance with DCP regulations and according to the 
manufacturer’s package insert or a prescribing practitioner’s (e.g., 
doctor or APRN) orders. Specifically, the bill allows pharmacists to 
additionally administer any vaccine:   2023SB-01102-R000221-BA.DOCX 
 
Researcher: JSB 	Page 4 	3/27/23 
 
1. on the adult immunization schedule and authorized by the FDA, 
2. not on the adult immunization schedule but for which the 
vaccine administration instructions are available on the CDC’s 
website, or 
3. prescribed by a prescribing practitioner for a specific patient. 
Under the bill, pharmacists can administer vaccines to any patient 
ages 18 or older. For patients who are ages 12-17, they may only do so 
with (1) the consent of the patient’s parent, legal guardian, or other 
person having legal custody or (2) proof that the patient is an 
emancipated minor. For current law’s limits on influenza vaccines for 
minors, the bill correspondingly (1) eliminates the requirement that an 
influenza vaccine only be administered if ordered by a health care 
provider and (2) aligns the parameters on consent with those described 
above for other vaccines under the bill.    
Before administering a vaccine, the pharmacist must make a 
reasonable effort to review the patient’s vaccination history to prevent a 
requested vaccine’s inappropriate use. 
Under existing law, DCP must adopt regulations requiring that 
pharmacists administering vaccines complete an immunization training 
course. The bill correspondingly extends this training requirement to 
pharmacists administering the additional vaccines the bill allows 
pharmacists to administer.   
Administering Epinephrine 
If a pharmacist has taken the training required to administer a 
vaccine (see above), the bill allows him or her to administer an 
epinephrine cartridge injector to a patient reasonably believed, based on 
the pharmacist’s knowledge and training, to be experiencing 
anaphylaxis. This authorization applies regardless of whether the 
patient has a prescription for an epinephrine cartridge injector.  
The pharmacist or his or her designee must call 9-1-1 either before or 
immediately after administering the epinephrine cartridge injector. The  2023SB-01102-R000221-BA.DOCX 
 
Researcher: JSB 	Page 5 	3/27/23 
 
pharmacist must also document the date, time, and circumstances in 
which he or she administered it, and maintain the documentation for at 
least three years. 
COVID-19, HIV, and Influenza Testing  
Under temporary federal rules, pharmacists can currently order and 
administer COVID-related tests. The bill permanently allows 
pharmacists to order and administer COVID-19, HIV, and influenza 
related tests if they are employed by a: 
1. hospital or 
2. pharmacy that has given the Department of Public Health (DPH) 
a complete clinical laboratory improvement amendment 
application for certification for a COVID-19, HIV, or influenza 
related test. 
They may do so for any patient ages18 or older. For patients who are 
at least age 12, but younger than 18, they may only do so with (1) the 
consent of the patient’s parent, legal guardian, or other person having 
legal custody or (2) proof that the patient is an emancipated minor. 
When pharmacists order and administer a test, they must give the 
patient the test results in writing and maintain a record of them for at 
least three years.   
Prescribing HIV Prophylaxis  
If a pharmacist orders and administers an HIV-related test and the 
result is negative, the pharmacist may prescribe and dispense to the 
patient pre-exposure or post-exposure HIV-related prophylaxis. The 
pharmacist may do so only if the (1) patient meets the criteria on the 
package insert and (2) prophylaxis is prescribed and dispensed in 
conformity with the state’s pharmacy laws. 
Sharing Test Results and HIV Prophylaxis Information With DCP 
Upon the DCP commissioner or his or her designee’s request, a 
pharmacist must share the results of a COVID-19, HIV, or influenza 
related test with DCP. Similarly, if a pharmacist prescribes HIV-related  2023SB-01102-R000221-BA.DOCX 
 
Researcher: JSB 	Page 6 	3/27/23 
 
prophylaxis, DCP may request a copy of the test results, prescription 
records, and any other documents the commissioner requires by 
regulations. (Presumably, the regulations DCP must adopt, as described 
below, will address applicable privacy laws.) 
Regulations Related to Testing and HIV Prophylaxis Prescribing  
The bill requires the DCP commissioner, in consultation with the 
DPH commissioner and Commission of Pharmacy, to adopt regulations 
to implement the bill’s testing and prescribing authorizations. The 
regulations must (1) identify qualifying training programs accredited by 
the CDC, the Accreditation Council for Pharmacy Education, or another 
appropriate national accrediting body and (2) establish a control and 
reporting system.  
§ 3 — OPERATING MOBILE PHARMACIES 
The bill allows retail pharmacies to apply to DCP for permission to 
operate a mobile pharmacy that offers (1) temporary clinics, vaccination 
events, or opioid antagonist training and prescribing events or (2) 
pharmacy services to an underserved community. DCP sets the 
application form and must approve it, in writing, before a mobile 
pharmacy can operate. DCP may inspect the mobile pharmacy as it finds 
necessary, including before it begins operations.  
With the advice and consent of the Commission of Pharmacy, the 
DCP commissioner may adopt regulations to implement the bill’s 
mobile pharmacy provisions. 
Operational Requirements 
Unless DCP approves an exception, mobile pharmacies cannot (1) 
operate in one place for more than seven consecutive days, (2) operate 
for more than 14 days within a five-mile radius of the prior mobile 
pharmacy location, or (3) serve as an overnight storage space for drugs. 
Mobile pharmacies must be supervised by a pharmacist. The 
pharmacy that operates them must: 
1. keep records indicating which drugs it removes from the 
pharmacy premises for use in the mobile pharmacy and which  2023SB-01102-R000221-BA.DOCX 
 
Researcher: JSB 	Page 7 	3/27/23 
 
ones it dispenses; 
2. update the pharmacy’s records within 24 hours after dispensing 
a drug through a mobile pharmacy;  
3. inventory and return unused drugs to the pharmacy premises by 
the close of business each day unless DCP waives the bill’s 
prohibition on storing drugs in the mobile pharmacy overnight;  
4. store drugs in a way that prevents diversion, and meets the 
storage conditions specified by drugs’ manufacturers;  
5. establish and maintain a patient communication plan to ensure 
patient access to prescription refills if the mobile pharmacy is 
unavailable; and  
6. store and handle controlled substances in conformity with DCP 
regulations, if the FDA allows mobile pharmacies to store 
controlled substances. 
DCP may order a mobile pharmacy to close if it determines that (1) it 
failed to comply with the bill’s requirements, (2) it is unsafe to store 
drugs in it or dispense them from it, or (3) there is insufficient security. 
§ 4 — UNSCHEDULED PH ARMACY CLOSURES AND 
PRESCRIPTION PICKUP LOCKERS 
The bill creates rules for pharmacies when they face an unscheduled 
closure (which the bill does not define), including customer and 
prescriber notification and planning requirements. It requires DCP to 
adopt regulations to (1) implement the bill’s provisions on unscheduled 
pharmacy closures and (2) allow and regulate prescription pickup 
lockers (see below). 
Plan’s Contents  
The bill requires retail pharmacies to have a plan to manage 
unscheduled closings and annually review and update it. The plan must 
also be given to and reviewed with all pharmacy personnel annually.  
The plan must include the name of:  2023SB-01102-R000221-BA.DOCX 
 
Researcher: JSB 	Page 8 	3/27/23 
 
1. the person responsible for notifying the Commission of 
Pharmacy about an unscheduled closing; 
2. the person responsible for updating the operation hours in the 
pharmacy’s electronic record system so that it will not accept 
electronically transmitted prescriptions during the unscheduled 
closing;  
3. the person responsible for updating the pharmacy’s telephone 
system during an unscheduled closing to (a) ensure orally 
transmitted prescriptions are not accepted during the 
unscheduled closing and (b) provide a message that alerts 
patients to the closure and their ability to obtain their 
prescriptions from a nearby pharmacy; 
4. all pharmacies located within a two-mile radius, or the next 
closest pharmacy if there is no pharmacy within that radius; and 
5. the person responsible for posting a sign stating the closure’s 
duration at the pharmacy’s entrance and at each entrance of the 
structure containing it, if any. 
Requirements During Unscheduled Closing  
When a pharmacy experiences an unscheduled closing, the 
pharmacist manager of the pharmacy or, if the pharmacy operates more 
than five pharmacy locations in Connecticut, the pharmacy district 
manager must: 
1. modify the pharmacy’s operating hours in its pharmacy’s 
electronic record system to prevent accepting electronically 
transmitted prescriptions during the unscheduled closing; 
2. adjust the pharmacy’s telephone system to prevent accepting 
orally transmitted prescriptions during the unscheduled closing; 
3. provide a telephone system message alert to patients notifying 
them that the pharmacy is closed and they may obtain 
medications from a nearby pharmacy;  2023SB-01102-R000221-BA.DOCX 
 
Researcher: JSB 	Page 9 	3/27/23 
 
4. post signs at the pharmacy’s entrance, and at each entrance of the 
structure if the pharmacy is located within another structure, 
stating that the pharmacy is closed, the duration of the 
unscheduled closing, and providing (a) a list of all pharmacies 
within a two-mile radius or (b) the next closest pharmacy if there 
is no pharmacy within a two-mile radius; and 
5. on the request of another pharmacy, transfer a prescription and 
reverse any third-party payor claims associated with the already 
dispensed prescription. 
Under the bill, the “pharmacy district manager” is the person who 
supervises at least three Connecticut pharmacies and is responsible for 
their activities, including staffing, payroll, and hiring. 
Dispensing Prescriptions That Are Awaiting Pickup at a Closed 
Pharmacy  
If a pharmacy verifies that another pharmacy is experiencing an 
unscheduled closing, on a patient’s request, it may dispense a 
prescription that is dispensed and waiting for pickup at the closed 
pharmacy. It may do so using information from the closed pharmacy, 
the electronic prescription drug monitoring program, or another source 
that the pharmacist believes is reasonably accurate. If a prescription is 
dispensed under these circumstances, the dispensing pharmacy must 
contact the closed pharmacy within 24 hours after it reopens to transfer 
the prescription.   
Under the bill, these transfers are subject to existing requirements for 
prescription transfers, which generally require the: 
1. transferring pharmacist to cancel the original prescription in his 
or her records and indicate in the records the pharmacy to which 
the prescription is transferred and transfer date and 
2. receiving pharmacist to indicate in his or her records the (a) 
transfer and the transferring pharmacy and pharmacist’s names, 
(b) original prescription’s issue date and number, (c) date the 
original prescription was first dispensed, (d) number of refills  2023SB-01102-R000221-BA.DOCX 
 
Researcher: JSB 	Page 10 	3/27/23 
 
authorized by the original prescription and complete refill record 
as of the transfer date, and (e) number of valid refills remaining 
as of the transfer date. 
The bill requires the pharmacy that experienced the unscheduled 
closure to give the dispensing pharmacy all information necessary for 
the transfer. It must also reverse any third-party payor claims associated 
with the transferred prescription within 24 hours after it reopens.  
Secure Prescription Pickup Lockers  
The bill requires DCP to adopt regulations on unscheduled pharmacy 
closures and include provisions on placing a “secured container” at a 
pharmacy that allows patients to collect dispensed prescriptions 
(prescription pickup lockers). 
Before adopting the regulations, DCP may temporarily allow the use 
of prescription pickup lockers. Pharmacies must first submit protocols 
on using these lockers to DCP for its written approval. They may only 
be approved if the lockers:   
1. (a) weigh more than 750 pounds or are affixed to the pharmacy 
building’s structure and (b) are located immediately adjacent to 
the pharmacy’s location;  
2. limit access to authorized pharmacy personnel and individuals 
retrieving prescriptions with a unique identification system; 
3. are under constant video surveillance; 
4. are able to maintain a record of all products placed inside and the 
date and time each individual prescription is accessed; and 
5. comply with any other DCP protocols ensuring patient 
confidentiality, protecting public health and safety, and 
preventing prescription diversion. 
BACKGROUND 
Federal PREP Act and Pharmacists’ Administration of Vaccines  
The federal Public Readiness and Emergency Preparedness Act  2023SB-01102-R000221-BA.DOCX 
 
Researcher: JSB 	Page 11 	3/27/23 
 
authorizes the federal Health and Human Services (HHS) secretary to 
issue declarations protecting certain covered persons from liability 
related to the administration or use of medical countermeasures (42 
U.S.C. § 247d–6d). Under this authority, the HHS secretary issued a 
declaration authorizing state-licensed pharmacists, under certain 
criteria, to (1) order and administer vaccinations to minors ages 3 and 
older and (2) order and administer COVID-19 tests. 
Related Bill 
sHB 6788, favorably reported by the General Law Committee, (1) 
establishes a new DCP registration for dispensing group practices and 
dispensing assistants that dispense prescriptions directly to patients, (2) 
authorizes pharmacists to refill prescriptions for certain legend devices; 
(3) authorizes pharmacists to prescribe emergency or hormonal 
contraception, (4) expands reasons for enforcement action against a 
pharmacy to include delaying patients’ access to prescribed drugs or 
other pharmacy services, and (5) makes minor changes to laws related 
to compounding pharmaceuticals.  
COMMITTEE ACTION 
General Law Committee 
Joint Favorable Substitute 
Yea 16 Nay 7 (03/09/2023)